The Federal Trade Commission has approved Cardinal Health’s application to sell Patient Care Infusion. The 4-0-1 approval comes after a public comment period. Cardinal Health’s divestment is part of a 2011 FTC settlement to resolve competition issues with its acquisition of three nuclear pharmacies from Biotech. Patient Care Infusion has the capacity and ability to operate reconstituted nuclear pharmacies that Cardinal had closed after completing its acquisition. The pharmacies are in Las Vegas, Albuquerque, and El Paso.
Full content: FTC Press Release
Related content: Observations on the Commission’s Evanston Remedy: When Is Divestiture, or Any Remedy, Not Appropriate for a Consummated Anticompetitive Merger? (Mark Botti, Akin Gump)
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
South Africa Approves Canal+ MultiChoice Deal
May 21, 2025 by
CPI
WhatsApp Co-Founder Undermines Antitrust Allegations Against Meta in Court Testimony
May 21, 2025 by
CPI
OpenAI Acquires Jony Ive’s io for $6.4B to Pioneer Post-Smartphone Devices
May 21, 2025 by
CPI
Dior Commits €2 Million to Labor Initiatives in Italian Antitrust Settlement
May 21, 2025 by
CPI
Indonesia’s Antitrust Watchdog Probes Potential Risks of Grab-GoTo Merger
May 21, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Industrial Policy
May 21, 2025 by
CPI
Industrial Strategy and the Role of Competition – Taking a Business Lens
May 21, 2025 by
Marcus Bokkerink
Industrial Policy, Antitrust, and Economic Growth: Some Observations
May 21, 2025 by
David S. Evans
Bolder by Design: Crafting Pro-Competitive Industrial Policies For Complex Challenges
May 21, 2025 by
Antonio Capobianco & Beatriz Marques
Competition-Friendly Industrial Policy
May 21, 2025 by
Philippe Aghion, Mathias Dewatripont & Patrick Legros